Clinical trials: Preserved Ejection Fraction
Heart Failure, Preserved Ejection Fraction
The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction
The aim of prospective, open label, single center, randomized controlled trial is to investigate the efficacy of enavogliflozin on exercise performance, diastolic dysfunction, and quality of life in patients with heart failure…
- Trial name
- ENRICH-PEF (NCT06350487)
- Testing
- SGLT2 inhibitor
- Where
- South Korea
- Volunteers
- 154 people
- Sponsor
- Samsung Medical Center
Chronic Heart Failure (CHF)
Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
This study was a multi-center, randomized, double-blind, parallel group, active comparator trial designed to evaluate the overall effect of LCZ696 compared to valsartan on cognitive function as assessed by the CogState…
- Trial name
- PERSPECTIVE (NCT02884206)
- Testing
- LCZ696, Valsartan
- Where
- 135 sites in United States, Argentina and 18 more
- Volunteers
- 592 people
- Sponsor
- Novartis Pharmaceuticals
Bacterial Overgrowth Syndrome Small Bowel, Heart Failure with Preserved Ejection Fraction
Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction
Single-center, double-blind, randomized, controlled intervention study of the effect of correction of bacterial overgrowth syndrome in the small intestine (SIBO) on cardiac function in patients with heart failure with preserved…
- Trial name
- SIBO-HFpEF (NCT06652087)
- Testing
- Rifaximin, Standard HFpEF treatment
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Diastolic Heart Failure
CMR Exercise Stress Testing in HFpEF
Patients of the University Hospital Göttingen with echocardiographic signs for diastolic heart failure and indication for right heart catheterisation will undergo additional diagnostic testing with CMR including exercise stress…
- Trial name
- HFpEF-Stress (NCT03260621)
- Testing
- stress CMR
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- University of Göttingen
Heart Failure, Heart Failure With Preserved Ejection Fraction
HeartShare: Combining Omics, Deep Phenotyping, and Electronic Health Records for Heart Failure Subtypes and Treatment Targets
HeartShare is a comprehensive study of heart failure, a common and serious medical condition which occurs when the heart is unable to keep up with the demands of the body, resulting in shortness of breath, fluid retention, and…
- Trial name
- NCT05873634
- Where
- 6 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Heart Failure
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure.
- Trial name
- 8212-Preserved (NCT06979362)
- Testing
- CDR132L
- Where
- 118 sites in United States, Canada and 7 more
- Volunteers
- 200 people
- Sponsor
- Novo Nordisk A/S
Heart Failure With Preserved Ejection Fraction (HFpEF
Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF
The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve.
- Trial name
- Rebalance-HF (NCT04592445)
- Testing
- Greater Splanchnic Nerve Ablation
- Where
- 26 sites in United States, Georgia
- Volunteers
- 150 people
- Sponsor
- Axon Therapies, Inc.
Heart Failure With Preserved Ejection Fraction
Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
The purpose of this study was to evaluate the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure(HF) hospitalizations in patients with HF with preserved ejection fraction.
- Trial name
- PARAGON-HF (NCT01920711)
- Testing
- LCZ696, Valsartan
- Where
- 715 sites in United States, Argentina and 41 more
- Volunteers
- 4,822 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Diastolic
Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
Heart Failure with preserved Ejection Fraction (HFPEF) accounts for 40-50% of all heart failure patients with a frequency of hospital admissions for acute decompensation and short and long term mortality similar to patients with…
- Trial name
- ROPA-DOP (NCT01901809)
- Testing
- Furosemide, Dopamine
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Johns Hopkins University
Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction
Incretin Therapies in Obesity-related HFpEF
The central hypothesis to be tested is that patients with obesity and heart failure with preserved ejection fraction (HFpEF) prescribed tirzepatide will demonstrate reductions in measured plasma volume.
- Conditions
- Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
- Trial name
- NCT07554638
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Columbia University
Heart Failure With Preserved Ejection Fraction and Visceral Fat
Prognostic Study of Visceral Fat and Heart Failure With Preserved Ejection Fraction
Obesity and heart failure with preserved ejection fraction (HFpEF) have multiple pathologic associations that affect the prognosis of HFpEF.
- Trial name
- NCT06338033
- Where
- China
- Volunteers
- 298 people
- Sponsor
- Chongqing Medical University
Heart Failure With Preserved Ejection Fraction
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFPEF) is common and deadly but without therapy. Inconclusive studies such as TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) suggest…
- Trial name
- SPIRRIT (NCT02901184)
- Testing
- Spironolactone, Standard care
- Where
- 78 sites in United States, Sweden
- Volunteers
- 2,000 people
- Sponsor
- Uppsala University
Chronic Kidney Disease 5D, Heart Failure
Cardio-fistular Recirculation in Patients With Chronic Heart Failure and Preserved Left Ventricle Ejection Fraction
This is a single-arm cohort study aimed to evaluate change of arteriovenous fistula volume blood flow / cardiac output ratio in patients with chronic heart failure (NYHA I-II classes) and with preserved ejection fraction as a…
- Conditions
- Chronic Kidney Disease 5D, Heart Failure, Heart Failure NYHA Class I, Heart Failure NYHA Class II
- Trial name
- NCT06394986
- Testing
- Hemodialysis session
- Where
- Russia
- Volunteers
- 20 people
- Sponsor
- Moscow Regional Research and Clinical Institute (MONIKI)
Acute Heart Failure
Acute Heart Failure With Preserved Ejection Fraction - COngestion Discharge Evaluation
The AHF-CODE preserved study is a prospective, non-randomized, monocenter study performed in patients with heart failure with preserved ejection fraction admitted for worsening heart failure.
- Trial name
- AHF-CODE-P (NCT04343430)
- Testing
- Clinical examination centered on congestion, Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography, Biological: Blood sample retrieved for biological assessment and biobanking
- Where
- France
- Volunteers
- 170 people
- Sponsor
- Central Hospital, Nancy, France
Heart Failure With Preserved Ejection Fraction, Diabete Type 2
The Effect of Addition of Metformin to SGLT2 In Diabetic Patients With Heart Failure With Preserved Ejection Fraction
a prospective open-label, randomized controlled study to evaluate the efficacy of the addition of metformin to SGLT2 in diabetic patient with preserved ejection fraction
- Trial name
- NCT06080802
- Testing
- Metformin
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- October University for Modern Sciences and Arts
Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke)
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion
Background: Atrial fibrillation (AF) is the most common heart rhythm disorder worldwide. Globally, there are 37.5 million people with AF.
- Conditions
- Atrial Fibrillation (AF), Atrial Fibrillation (Prevention of Stroke), Atrial Fibrillation New Onset, Non Valvular Atrial Fibrillation
- Trial name
- BIO-AF (NCT06949319)
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Nedim Tojaga
Pulmonary Hypertension
Screening and Phenotyping of Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction .
Left-sided heart failure (HF) is known to cause pulmonary hypertension (PH), but the development and severity of PH in HF is highly variable, and contributing factors are not fully understood.
- Trial name
- NCT07082400
- Testing
- right heart catheter
- Volunteers
- 100 people
- Sponsor
- Sohag University
Heart Failure
Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)
Researchers are studying the effect of a single dose of oral myeloperoxidase on heart failure versus placebo.
- Trial name
- NCT03611153
- Testing
- AZD4831 Oral Myeloperoxidase Inhibitor
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Heart Failure With Preserved Ejection Fraction
Chemoreflex Sensitivity in HFpEF
Patients with heart failure and a preserved left ventricular ejection fraction (HFpEF) almost invariably complain of exertional breathlessness.
- Trial name
- CHEMO-HFpEF (NCT06309537)
- Testing
- chemoreflex evaluation
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Istituto Auxologico Italiano
Hypertension, Pulmonary
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
Researchers are looking for new ways to treat people with a type of pulmonary hypertension called combined postcapillary and precapillary pulmonary hypertension (Cpc-PH).
- Trial name
- HARMONIZE (NCT06814145)
- Testing
- Sotatercept
- Where
- 57 sites in United States, Belgium and 10 more
- Volunteers
- 440 people
- Sponsor
- Merck Sharp & Dohme LLC